



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 8449-128-999	APPLICATION NO. 09/668,724
	APPLICANT Srivastava et al.	
	FILING DATE September 22, 2000	GROUP 1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CY	C02	Binder and Srivastava, 2004, Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133.
	C03	Binder <i>et al.</i> , 2002, Naturally formed artificially reconstituted non-covalent alpha 2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity. Cancer Immunity 2:16-24.
	C04	Basu <i>et al.</i> , 2001, CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303-313.
	C05	Herz and Strickland, 2001, LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. 108:779-784.
	C06	Goto and Tanzi, 2002, The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation. J. Mol. Neurosci. 19:37-41.
CY	C07	The Merck Manual of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872.

EXAMINER <i>Chrupalix</i>	DATE CONSIDERED <i>2/1/05</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	